NCT02913430: Phase II Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen

NCT02913430
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must have ER+ tumor(s)
Exclusions: Patients with symptomatic, untreated CNS metastases that require treatment
https://ClinicalTrials.gov/show/NCT02913430

Comments are closed.

Up ↑